Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

14.75 -0.04 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 584,299
Open 14.75
Bid (Size) 13.90 (1)
Ask (Size) 14.76 (1)
Prev. Close 14.79
Today's Range 14.26 - 14.84
52wk Range 8.525 - 22.76
Shares Outstanding 58,041,410
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Deciphera Pharmaceuticals Stock Jumped This Week
The company's lead therapy received an FDA Breakthrough Therapy designation. 
Via The Motley Fool
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
 
Via Benzinga

Performance

YTD
-7.47%
-7.47%
1 Month
+0.48%
+0.48%
3 Month
-6.88%
-6.88%
6 Month
-18.51%
-18.51%
1 Year
+57.75%
+57.75%

More News

Read More
Where Deciphera Pharmaceuticals Stands With Analysts
Via Benzinga
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed
Via Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
Via Benzinga
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
Via Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Deciphera Pharmaceuticals Stock Is Nosediving
Via Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.